$RDGL - News Out - Vivos Inc Signs Memorandum of U

$RDGL - News Out - Vivos Inc Signs Memorandum of Understanding with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy
#marketing #cancer #trader #investor #business #healthcare #health



Richland, WA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (RDGL) selected its first clinic for commercial sales of IsoPet

Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, announced today that the Vista Veterinary Hospital in Kennewick WA, located near Vivos’ headquarters, has been selected for the commercial launch of IsoPet® therapy. After several meetings with the clinic’s veterinarian owners, a Memorandum of Understanding has been signed.

Vivos’ strategy is to partner with several regional clinics across the country using this pilot program to provide practical experience to be shared with other potential regional clinic partners. Having selected a local clinic as the pilot provider of IsoPet™ therapy will make for cost-effective frequent site visits for the assistance of facility set-up, certification training, and radioactive material handling licensing. Certification training and the process of acquiring a Radioactive Material License for the clinic from the Washington State Department of Health has begun.

It is expected that as the successful results of the therapies become known, pet owners from as far as Spokane, Seattle and Portland will seek to have their affected animals treated at the Vista Clinic. It is estimated that more than 9 million people live within 250 miles of Kennewick.

Dr. Mike Korenko, Vivos CEO stated “Best management practice dictates that we pilot partnering with a private clinic prior to expanding to other regional clinics across the county. We will gain practical experience, such as the effectiveness of our certification training and the time and effort required to obtain the Radioactive Material License. This will optimize the process of engaging with other treatment centers”.

As noted in a previous press release, the company will introduce IsoPet® to the larger veterinarian community at the annual Veterinary Cancer Society Conference to be held in Louisville, KY October 17-20, 2018.

About Vivos Inc. (RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.